Clinical Trial: Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837389) titled 'Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors' on Feb. 16.

Brief Summary: 1. Primary objectives of study:To valuate the tolerability and safety of JY306 in patients with relapsed or refractory CD70 + malignant hematological tumors.

2. Secondary objectives of study:To conduct a preliminary Evaluation of the Efficacy, Pharmacokinetics, and Pharmacodynamics of JY306 in Patients with Relapsed or Refractory CD70+ Malignant Hematological Tumors.

Study Start Date: Feb. 15

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Hematolo...